-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Following Innovent Bio, Junshi Bio, BeiGene, and Kangfang Bio, Henlius will become the latest Chinese biotech company trying to bring PD-1 inhibitors to the U.
According to the company’s financial report for the first half of 2022, based on the results of the meeting with the US FDA, Henlius plans to start a slulimumab (Hans-like) in the second half of 2022 for US extensive-phase small cells Bridging trial in patients with lung cancer (ES-SCLC)
Slulimumab (Hans-like)
In December 2021, Henlius announced that slulimumab combined with chemotherapy became the world's first PD-1 to achieve overall survival (OS) benefit in a Phase III trial of first-line ES-SCLC treatment
The world's first
Prior to this, both Eli Lilly/Innovent and Junshi Bio received FDA Complete Response Letters (CRLs) for their respective checkpoint inhibitors, requesting the inclusion of an international multi-disciplinary team that is more representative of the U.
Represents the U.
About slulimumab (Hans-like)
Henlius is an innovative anti-PD-1 monoclonal antibody independently developed by Henlius.
2021.
2021.
2022.
2022.
(click to read related)
2022.
2022.
2022.
2022.
According to previous reports from GBI, in the first half of 2022, Henlius will cooperate with Getz Pharma, Eurofarma and Abbott on products such as Handayuan, Hanlikang, Hanquyou and Hanbeitai, respectively, and the external authorization covers Pakistan, Nigeria, Brazil and other 27 emerging market countries in Asia, Africa, Europe and Latin America
GBI27 emerging market countries
Funding from the out-licensing transaction also provides continued support for Henlius’ innovative drug pipeline
